Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis for HOLX:

Technical Analysis

The stock is currently showing bearish signals:

• Price has declined 12.28% YTD and 13.55% over the past year
• RSI reading of 29.4 indicates oversold conditions
• Currently trading at $63.24, near its 52-week low of $62.94

Fundamental Analysis

Key Financial Metrics:

• P/E Ratio: 20.01x
• Market Cap: $14.19B
• Revenue Growth: 16.7% organic growth excluding COVID-19 in recent quarter

Recent Developments

1. Q1 2025 Results:

• Revenue: $1.02B (in line with expectations)
• Non-GAAP EPS: $1.03 (beat consensus)
• Reduced FY25 revenue guidance to $4.05-4.10B from $4.15-4.20B

2. Analyst Consensus:

• Mean Price Target: $84.25 (32.6% upside potential)
• Rating: "Moderate Buy" based on:
  • 6 Strong Buy
  • 1 Moderate Buy
  • 11 Hold ratings

Growth Drivers & Risks

Strengths:

• Strong performance in GYN Surgical business
• Robust margins and healthy balance sheet
• Consistent organic growth excluding COVID-19 impact

Risks:

• Currency headwinds affecting international performance
• Declining COVID-19 testing revenues
• Recent guidance reduction impacting investor confidence

Conclusion

SELL recommendation based on:

1. Deteriorating technical indicators
2. Recent guidance reduction
3. Ongoing currency headwinds
4. Declining COVID-19 revenue impact

While long-term fundamentals remain solid, the stock appears likely to face continued pressure in the near term. Consider waiting for technical indicators to show signs of reversal before establishing new positions.

Based on the provided data and recent market developments, here's the price prediction for HOLX stock in 2025:

HOLX stock is expected to reach $84.25 by end of 2025, representing a 33% upside from current levels, driven by strong profitability and execution despite recent revenue headwinds. The company's reduced FY2025 revenue guidance to $4.05-4.10 billion from $4.15-4.20 billion due to currency headwinds and weakness in breast health capital sales has created near-term pressure, but maintained EPS guidance suggests operational efficiency.

The technical analysis shows the stock is currently oversold with RSI at 29.4, suggesting potential for a technical rebound from current levels around $63.24. The Fibonacci support levels indicate strong support at $63.68, with next resistance at $71.41.

The S1 support level for HOLX Stock is $63.02 ,The R1 resistant level for HOLX Stock is $65.6.

As of the end of day on 2025-02-21, the price of HOLX Stock was $64.5.

The target price for HOLX Stock according to analyst rating is 83.54, with the highest price target at 90.00 and the lowest at 75.00. Analysts have a Hold rating on HOLX Stock overall.

The market cap of HOLX is $14.5B.

Based on the provided data and recent market developments, here's a comprehensive analysis of whether HOLX is overvalued:

Technical Analysis

The stock is currently showing bearish signals with RSI at 27.10, indicating oversold conditions. The stock is trading below both its 20-day (68.97) and 200-day (76.63) moving averages, suggesting a strong downward trend.

Valuation Assessment

The stock's current valuation metrics show:

• P/E ratio increased significantly from 12.28 (2022) to 37.87 (2023)
• EV/EBITDA rose from 7.81 to 13.53
• P/S ratio expanded from 3.29 to 4.28

Market Position The stock has underperformed significantly, declining 14.1% from its 52-week high of $84.67. Recent analyst coverage maintains a "Moderate Buy" rating, though the stock is trading well below the average analyst price target of $88.75.

Conclusion HOLX is not overvalued at current levels due to:

1. Oversold technical conditions with RSI below 30
2. Recent price decline creating better entry points
3. Strong projected earnings growth of 8.9% for fiscal 2026
4. Trading below analyst consensus price targets
5. Healthy revenue growth projections of 3-4% for fiscal 2025

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. It operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system and Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment products include Horizon DXA Systems and Fluoroscan Insight FD.

Based on the provided data and recent market trends, here is the 2030 price prediction for HOLX stock:

HOLX stock is projected to reach $95-100 by 2030, driven by continued strength in the company's diagnostics business and strategic expansion in women's healthcare technology. The company's focus on operational efficiency and strong profitability metrics, despite recent revenue guidance reductions, supports this growth trajectory. Market analysts maintain a "Moderate Buy" consensus with a mean price target of $84.25 in the near term, indicating steady upward momentum.

HOLX has a total of 6990 employees.